Advanced search
Start date

Antitumor mechanisms of OncoTherad nano- immunotherapy involving toll-like 4 receptor-mediated signaling pathway, immune checkpoints and monoamine oxidases: clinical implications in bladder cancer

Grant number: 22/04796-3
Support Opportunities:Scholarships in Brazil - Master
Effective date (Start): September 01, 2022
Effective date (End): February 29, 2024
Field of knowledge:Biological Sciences - Morphology - Anatomy
Principal Investigator:Wagner José Fávaro
Grantee:Gabriela Cardoso de Arruda Camargo
Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil


Bacillus Calmette-Guerin (BCG) immunotherapy is the most effective form of intravesical therapy for the prophylaxis of recurrence and progression of non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is often associated with local and/or systemic adverse effects, including sepsis, in addition to tumor recurrence in up to 40% of cases. The incidence of these effects is significantly reduced with the use of chemotherapeutic agents. However, the response to intravesical chemotherapy is incomplete and tumor recurrence is high. Despite this, to date, there is no other therapy more effective than BCG on the market. In both Brazil and USA, the manufacture and distribution of BCG suffers from constant interruptions, which can negatively impact the treatment of patients with bladder cancer. Without this treatment, such patients have a high risk of tumor recurrence and progression. The surgical option, partial or total cystectomy, is often associated with high morbidity and mortality rates. Also, for some patients, cystectomy is not an available option due to the presence of comorbidities. Thus, new treatment modalities for patients with high-grade NMIBC, for whom BCG therapy has failed or is contraindicated, are increasing due to the development of new drugs. Immunotherapy has become a promising cancer therapy, improving the prognosis of patients with different types of cancers, and offering the possibility of long-term disease remission. Since NMIBC is sensitive to immunotherapy, immunomodulators that act as agonists of the immune system are considered promising candidates for the development of more effective treatments for NMIBC, without the accompanying side effects. In this scenario, a new perspective is represented by the OncoTherad® nanoimmunotherapy. OncoTherad® is a nanostructured inorganic phosphate complex associated with glycosidic protein (MRB-CFI-1), developed by the University of Campinas/Brazil, which has immunomodulatory and antitumor properties. This project is a prospective study that aims to evaluate the therapeutic and immunological effects of OncoTherad® nanoimmunotherapy in patients with NIMBC unresponsive to BCG (refractory, relapsed or intolerant) and/or intravesical chemotherapy, as well as to verify the cellular mechanisms triggered by this therapy. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.